Catalog makes Hartwig Medical Database easily searchable

Hartwig Medical Foundation maintains a catalog of the Hartwig Medical Database with whole-genome data on full tumor genomes: https://catalog.hartwigmedicalfoundation.nl. The database currently contains data on over 5,800 patients, including treatment and response data. In addition, this database contains RNA sequencing data from more than half of the patients.
Hartwig Medical Foundation’s mission is to provide the best possible care for today’s patient as well as the patient of tomorrow. An important part of this is making genomic and relevant clinical data available to research groups, with consent from the patients involved. The public catalog of Hartwig Medical Database makes it easy to gain insight into the available data, enabeling a quick and easy overview if there are tumor genomes in the database of interest to the researcher.

The catalog is interactive and the database can be viewed through flexible visualizations of different data types in multiple dimensions. Filtering is possible per data type, e.g. tumor type, biopsy location, age, gender, treatment given, treatment outcome and RNA availability.
This is the world’s largest publicly available dataset of its kind. It is available free of charge for research to improve the care for cancer patients of today and tomorrow. Hartwig Medical Foundation is grateful for the cooperation of so many patients, they have chosen to share their data for the benefit of science and other patients.
For the conditions and procedures for requesting access to the data, please visit our website.
Hartwig Medical Foundation collects data in collaboration with the CPCT, the Netherlands Cancer Institute and more than 40 Dutch hospitals with the consent of patients in various studies.
This unique source is continuously growing with increasing adaptation of complete genome diagnostics in regular healthcare in the Netherlands. Cancer of unknown primary origin is the first indication with a reimbursement title for this test and shows clearly the added value for patients in daily practice.
All news
Also read
The Importance of Analyzing the DNA of Rare Tumors
One in four patients has a cancer type that is considered rare, meaning it occurs in fewer than six out …
Warnyta Minnaard represents patient interests and possibilities
Frank van Wijck, science journalist Warnyta Minnaard has been a member of Hartwig Medical Foundation’s Data Access Board (DAB) since February …
Update on the GENAYA Project: DNA from 500 Young Cancer Patients Analyzed
Should young people with cancer receive different treatment than older patients? We suspect they do, but there’s currently not enough …
In our profession, we need to know everything about the patient, but we also want to know as much as possible about the patient’s tumor.